A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Patients With Kidney Transplant

Mise à jour : Il y a 4 ans
Référence : NCT02547220

Femme et Homme

Extrait

To evaluate the efficacy of Cinryze® given for the treatment of acute antibody-mediated rejection (of renal allograft) (AMR) in kidney transplant recipients as measured by the proportion of subjects with new or worsening transplant glomerulopathy (TG) at 6 months after treatment initiation.


Critère d'inclusion

  • Acute Antibody-Mediated Rejection (AMR)


Liens